Phaseline

Companies › Institut Pasteur

Institut Pasteur: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 2 Phase 3, 1 Phase 1, 1 Phase 4, 1 Phase 2; Infectious disease, Immunology, Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Moxifloxacin
Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor
–Phase 3Hidradenitis Suppurativa; Multidrug- and Rifampicin-resistant Tuberculosis; Triple Negative Breast Cancer; Tuberculous MeningitisFeb 2027
MOPEVAC-Las vaccine
Live-attenuated Lassa virus vaccine
–Phase 1Lassa FeverApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04722978MoxifloxacinPhase 3Triple Negative Breast CancerOncologyJun 2026
NCT05821478MoxifloxacinPhase 3Hidradenitis SuppurativaImmunologyFeb 2027
NCT05381194MoxifloxacinPhase 4Multidrug- and Rifampicin-resistant TuberculosisInfectious diseaseDec 2027
NCT07227779MoxifloxacinPhase 2Tuberculous MeningitisInfectious diseaseMar 2028
NCT07833436MOPEVAC-Las vaccinePhase 1Lassa FeverInfectious diseaseApr 2028

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Anhui Zhifei Longcom Biologic Pharmacy Shanghai Longwood Biopharmaceuticals Aimei Vacin BioPharm (Zhejiang) Huahui Health InventVacc Biologicals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.